Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option : a cross-study comparison of the CANDOR and EQUULEUS studies - Leleu, Xavier (Service d'Hématologie et Thérapie cellulaire. CHU and Inserm) ; Beksac, M. (Department of Hematology. Ankara University) ; Chou, T. (Niigata Cancer Center Hospital) ; Dimopoulos, Meletios (Hematology and Medical Oncology. Department of Clinical Therapeutics. National and Kapodistrian University of Athens School of Medicine) ; Yoon, S. S. (Department of Internal Medicine. Seoul National University) ; Prince, H. M. (Epworth Healthcare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ; Pour, L. (University Hospital Brno (República Txeca)) ; Shelekhova, T. (Clinic of Professional Pathology) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica). Tisch Cancer Institute) ; Khurana, M. (Clinical Development. Oncology. Amgen Inc) ; Zhang, J. (Global Biostatistical Science. Amgen Inc) ; Obreja, M. (Global Biostatistical Science. Amgen Inc) ; Qi, M. (Hematology and Oncology. Janssen Research and Development. LLC) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Siegel, D. (John Theurer Cancer Center. Hackensack University Medical Center) ; Universitat Autònoma de Barcelona